Biotech
-
1.4KModerna’s (MRNA) Bloated Market Cap & mRNA Vaccine Thesis Under Fire
Shares of Moderna (NASDAQ: MRNA) recently spiked over $400, giving the mRNA vaccine maker a market cap of about $200 billion, greater...
-
1.8KCytoDyn (CYDY) Shorts Throttle Up Bashing Ahead of August Super News Cycle
Short attack timed to capitalize on consolidation and thin trading The Oregonian misquotes and twists statements taken out of context SEC case...
-
2.1K2CytoDyn’s Preliminary Phase 1b/2 Cancer Results Likely to Receive Breakthrough Therapy Designation (BTD)
CytoDyn Inc. (OTCMKTS: CYDY) announced excellent preliminary results from its Phase 1b/2 clinical trial in metastatic triple negative breast cancer...
-
2.0KCytoDyn (CYDY) at Crossroads: Past and Current Leadership Collide in Epic Grudgematch
Latest 8-K filing settles dispute for $7.6 million but paves way for Pestell share repurchase at par 13-D Group is outspoken but...
-
4.8KEnzolytics (ENZC) Takes on HIV Heavyweight Gilead Sciences
The cocktail of drugs given to HIV patients has been dominated by Gilead Sciences (GILD) for over a decade. They are the...
-
1.8K14 Biotech Stocks to Watch: AMRN AVXL RGBP SBFM
U.S. biotech stocks are off to a strong start this week. It didn’t take long for investors to get over the Fed’s...
-
2.8KTodos Medical (TOMDF) with a $22 Million Market Cap Taking on Pharma Giant Pfizer for COVID-19 Antiviral
Vaccines have less efficacy with COVID-19 variants Key 3CL protease inhibitors shows promise for any COVID-19 variants, and potentially all coronav...
-
1.7KAikido Pharma’s (AIKI) Clinical Trial Results Continues to Validates Gilead’s $21 Billion Purchase of Immunomedics
Aikido Pharma Inc. (NASDAQ: AIKI) announced excellent phase 1 data at the annual ASCO meeting. The data was presented by Dr. Scott...
-
3.7KEnzolytics (ENZC) Working With Intel (INTC)
Intel whitepaper highlights case study on Enzolytics COVID-19 and HIV potential for neutralization of both viruses. Bear case is nothing but FUD....
